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ABSTRACT OF THESIS 
 
 
DEVELOPING A WORKFLOW TO EVALUATE MEDICATIONS FOR REPURPOSING 
USING HEALTH CLAIMS DATA: APPLICATION TO SUBSTANCE USE DISORDERS 
 
 
Healthcare big data are a growing source of real-world data with which to identify and 
validate medications with repurposing potential. Previously, we developed a claims-based 
workflow to evaluate medications with potential to treat stimulant use disorders. In order to test 
the workflow, the framework was applied in the context of opioid use disorders (OUDs), for 
which there are medications with known efficacy. Using the Truven Marketscan Commercial 
Claims Database, a nested case-control analysis was conducted to determine the association 
between OUD medications (buprenorphine, naltrexone) and remission. Cases were defined as 
enrollees with a remission diagnosis and matched (1:4) to controls (individuals without 
remission) using incidence density sampling, with age group, sex, region, and index year as 
additional matching variables. After adjusting for behavioral health visits, polysubstance use 
disorders, and psychiatric disorders using conditional logistic regression, the odds of OUD 
medication exposure were 3.8 (99% confidence interval: 3.0 – 4.9) times higher in cases than 
controls. Evaluation of angiotensin converting enzyme inhibitors (e.g. lisinopril) as a negative 
control revealed no significant association between the medication and remission. This work 
demonstrates the feasibility of using administrative health claims data to evaluate the 
effectiveness of medications to treat substance use disorders.  
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CHAPTER 1.  INTRODUCTION 
1.1 MEDICATION REPURPOSING 
Drug repurposing, a complementary approach to de novo drug discovery1, is the process of 
identifying novel indications for existing medications. Medication repurposing offers several 
advantages over de novo drug discovery in that it is more cost effective and the medication can be 
brought to market more rapidly to treat the additional disease since it will have already been 
approved by regulatory agencies1. Generally, identification of a biological target is a prerequisite 
for de novo drug discovery, which can be conceived of as a translational approach (molecular target 
à clinic) to therapeutic discoveries. Similarly, many systematic approaches to drug repurposing 
(e.g. computational screening of genetic and chemical libraries) are best suited to medical 
conditions for which biological mechanism(s) of disease are known2. However, conditions with 
complex underlying etiology, such as neuropsychiatric and substance use disorders, represent 
challenges that call for reverse-translational approaches3.  
In response to limitations of the translational approach to drug development, researchers 
have developed strategies to implement reverse-translational drug repurposing. One such strategy 
is to match diseases based on phenotype similarity and then map those relationships to known 
molecular disease pathways4–6. Xu and colleagues7 recently applied this approach to glioblastoma 
subtypes exhibiting distinct molecular and clinical phenotypes to prioritize medications likely to 
be most effective for a given subtype. A related approach is to match diseases based on common 
Food and Drug Administration (FDA)-approved medications and predict novel drug uses based on 
shared treatment profiles8. Ultimately, reverse-translational medication repurposing is a promising 
strategy and can be particularly effective when the etiology of a disorder is complex and a biological 




1.2 REVERSE-TRANSLATIONAL MEDICATION REPURPOSING WORKFLOW 
The growing volume, access, and quality of healthcare data provides a valuable resource 
for engaging in drug repurposing from a reverse-translational perspective. Healthcare data are 
available in a variety of forms including health claims, electronic health records, images, and even 
social media9. Administrative health claims data are one source of healthcare data that provide a 
longitudinal source of information from inpatient and outpatient services, including demographics, 
diagnoses, procedures, and prescriptions. As such, health claims data are a good source of real-
world health data to use for exploratory analyses to identify medications with potential for 
repurposing. 
Figure 1 displays data processing workflow we previously developed for using health 
claims data to evaluate medications for repurposing10. The first step in the process is to identify the 
sample of interest, which will likely be accomplished using diagnosis codes. Once the sample of 
interest has been identified, the next step is to identify candidate medications for evaluation. This 
can be accomplished through a data-driven strategy (e.g. hypothesis generation via data mining) or 
using a priori knowledge. Prescription medications are labeled using National Drug Codes, which 
can be aggregated into therapeutic classes and Generic Product Indicators using resources like the 
Medi-Span® data dictionary11. Using the Generic Product Indicator (GPI), characterizing 
prescriptions within a sample can be done at the level of root classification (e.g. antidepressants), 
medication subclass (e.g. norepinephrine-dopamine reuptake inhibitors), or specific medications 
(e.g. bupropion). In describing medication characteristics, it is advisable to provide a measure of 
adherence and duration that the medication is prescribed to the sample. Once the sample has been 
identified and medication(s) selected, the workflow takes on characteristics of a retrospective 
pharmacoepidemiologic study. Claims data provide an open cohort, so it is necessary to define an 
index date relative to some characteristic of each individual as a proxy for the study start date. The 
index date is important for defining a baseline period during which sample characteristics can be 




medication or combinations of medications prescribed to an individual, while the outcome may 
vary considerably depending on the medical condition of interest. The outcome may be determined 
from diagnosis or procedure codes, or it could be feature(s) aggregated over a period of time, such 
as healthcare utilization and expenditures. Clearly defined temporal parameters for exposures and 
outcomes are necessary when designing the retrospective analysis. For most studies, defining 
exposure should follow the new-user design12, wherein the exposure group includes new 
medication users who have no evidence of a prescription for some period of time (e.g. 6 months) 
prior to the index date. Similarly, when choosing an outcome, it is important to be mindful of 
temporal logistics. Specifically, the outcome must occur after initiation of the medication and fall 
within a time-frame that is consistent with the medication’s putative therapeutic effect based on 
clinical understanding of the disease. Once the retrospective analysis specifications have been 
determined, statistical analyses should be implemented according to the outcome. If the 
retrospective analysis identifies a beneficial health outcome of a medication, plans should be made 
to validate the findings from both a multimodal and multidisciplinary perspective. Initially, the 
analysis should be repeated using alternate data sources representing different types of information 
Repurposing Workflow
Identify sample Identify candidate medications














Figure 1. Workflow for reverse-translational medication repurposing using health claims 
data. Reverse translational medication repurposing begins with sample and candidate 
medications identification, followed by selection of medications for retrospective analysis. 




(e.g. electronic health records) or populations (e.g. commercially-insured vs. Medicaid). 
Subsequently, the findings can be pursued in a multidisciplinary context to understand how the 
medication is working (mechanism of action) using cell-based assays, recapitulate the finding in 
animal models, and ultimately test the therapy in human clinical trials.  
1.3 APPLICATION OF WORKFLOW TO STIMULANT USE DISORDERS 
In the initial development of the framework, the reverse-translational medication 
repurposing workflow was applied to stimulant use disorders. Using the Truven MarketScan 
Commercial Claims Database, individuals (18-64 years) with a cocaine or amphetamine use 
disorder diagnosis were identified based on International Classification of Disease, Ninth Revision, 
Clinical Modification (ICD-9-CM) codes. Notably, the diagnostic codes for methamphetamine use 
disorder are categorized under ‘amphetamine’ abuse and dependence, so the term amphetamine(s) 
is used to describe this sample. However, epidemiological findings from the Treatment Episode 
Dataset suggest that most (94%) individuals in the amphetamines category represent individuals 
using methamphetamine13. Having identified 82,137 and 110,015 individuals with amphetamine 
and cocaine use disorder, respectively, the next step was to identify candidate medications. To do 
so, pharmacy claims were screened for the most commonly prescribed medications to individuals 
in our sample. Bupropion (i.e. Wellbutrin®, Zyban®), which is a norepinephrine-dopamine reuptake 
inhibitor and nicotinic acetylcholine receptor antagonist that is prescribed for depression and 
smoking cessation, was the most commonly prescribed medication among individuals with a 
stimulant use disorder. Since bupropion also has potential as an indirect agonist replacement 
therapy for stimulant use disorders14, it was selected to be evaluated for potential to treat stimulant 
use disorders. The outcome of interest was an ICD-9-CM diagnosis of remission. Using a 
retrospective cohort analysis, we found that filling a prescription of bupropion within 30 days of 
first documented stimulant use disorder diagnosis increased odds of a subsequent remission 




use disorder, but not those with a cocaine use disorder. The finding that bupropion was associated 
with remission only among individuals with amphetamine use disorder (and not cocaine) was 
consistent with the preponderance of evidence from clinical studies14, bolstering credibility for the 
validity of the workflow. 
1.4 OPIOID USE DISORDER TEST CASE 
Since there are no FDA-approved pharmacotherapies to treat stimulant use disorders, there 
is no benchmark (i.e. positive control) against which to test the findings from administrative 
data. In order to further develop the medication repurposing workflow for application to 
substance use disorders, the purpose of this study was to establish the feasibility of using 
administrative health claims data to assess the real-world effectiveness of medications used to 
treat substance use disorders. Unlike the case for stimulant use disorders, there are medications 
with FDA-approval to treat opioid use disorder (OUD). Specifically, buprenorphine products and 
naltrexone are identifiable in pharmacy claims data and are FDA-approved to treat OUD. 
Buprenorphine significantly increases treatment retention and negative urine samples, and 
reduces opioid craving in randomized controlled trials of individuals with OUD15,16. When 
patients adhere to treatment (≥ 80%), naltrexone increases retention and abstinence by nearly 3-
fold versus placebo or no pharmacological treatment17. To establish the groundwork for future 
studies on stimulant use disorders, we evaluated the effectiveness of medications known to treat 
OUD in the context of our medication repurposing workflow.    
 
CHAPTER 2. METHODS 
2.1 DATA SOURCE 
Data were obtained from individuals enrolled in the Truven Marketscan Commercial 




collection of inpatient, outpatient, professional, and pharmacy health claims from commercially-
insured individuals and their spouses and dependents, which represented about 120 million lives 
during the observation period18.  
2.2 COHORT 
Individuals with an ICD-9-CM or ICD-10-CM diagnosis of OUD (Appendix A) were 
eligible to be included in the cohort. The ICD-9-CM codes used to identify OUD were a 
conservative selection based on previous research19,20 that did not include poisonings or remission 
codes. Corresponding ICD-10-CM codes that included the terms ‘abuse’ or ‘dependence’ were 
also included. A previous validation study of ICD-9-CM diagnostic codes for substance use 
disorder revealed that these codes have high specificity (92-99%), but only moderate sensitivity 
(54-78%)21.  
2.3 STUDY DESIGN 
The index month was defined as the month during which the first OUD diagnosis was 
observed (Figure 2). Baseline measures were evaluated during the six months prior to and 
including the index month. In order to be included in the final cohort, enrollees must have been 
between the ages of 18 to 64 years during the index month, had six months of eligibility prior to 
the index month (baseline), prescription drug and mental health insurance coverage at 
baseline, and valid enrollment information. Of the 562,850 Truven enrollees with an OUD 
diagnosis, 312,214 had at least six months of eligibility in the dataset prior to the index date with 
valid enrollment information. A further 153,022 met all inclusion criteria, such that they were 
between the ages of 18 and 64, had prescription and mental health insurance coverage, and no 






Figure 2. Nested case-control study design using incidence density sampling. Each enrollees’ 
index date was defined as the first observed opioid use disorder (OUD) diagnosis. Baseline 
covariates were measured in the 6 months prior to the index date. Enrollees were then followed 
until they received a remission diagnosis (green dot; case) or until they were censored (blue dot; 
controls, i.e. enrollees without remission). Cases were matched with controls for time at risk. 
Medication exposure was determined in the up to 6 months leading up to the lookback date.  
2.4 INCIDENCE DENSITY SAMPLING 
Cases were identified from the final cohort if they had a remission diagnosis (Appendix B) 
following their index month. Of the final cohort, 3,902 received a remission diagnosis following 
the index date and were classified as cases. This left 149,120 potential controls (enrollees without 
a remission diagnosis) to use for matching. Controls were selected from the eligible 
sample and matched 4:1 with cases using incidence density sampling22. Incidence density 
sampling requires that controls be ‘at risk’ for the same period of time as cases without having 
received a remission diagnosis (Figure 2). As such, the lookback date was defined as the month of 
remission for cases and as the month in which controls had been at risk for the same period of 
time as their matched case (i.e. control index month + time at risk of matched case). Additional 














year). All but four cases were matched with four controls, resulting in 3,898 cases and 15,592 
controls (Figure 3). 
 
Figure 3. Inclusion diagram for opioid use disorder cohort and nested case-control analysis. 
Of the 562,850 enrollees with an opioid use disorder (OUD) diagnosis, 153,022 met all inclusion 
criteria to be included in the cohort. From that cohort, 3,898 (2.5%) cases (i.e. enrollees with 
remission) were identified and matched (1:4) with controls (n=15,592; enrollees without 
remission) on baseline age group, sex, region, and index year. *Four cases were not matched to 
controls. Jan: January; Dec: December; Mos: Months. 
2.5 EXPOSURE 
Exposure was defined as any OUD medication (i.e., buprenorphine, buprenorphine-
naloxone, and naltrexone) prescription compared to no OUD medication prescription. 
Prescriptions for OUD medications were identified from pharmacy claims using Medi-Span®’s 
GPIs (Appendix C). As a proxy for adherence, proportion of days covered (PDC) was calculated 
as a sum of the non-overlapping days’ supply during the lookback period divided by the number 
of days during that period multiplied by 100. Exposure was then defined as a dichotomous 
variable indicating presence (1) or absence (0) of at least 80% PDC during the lookback 
period. For this analysis, only pharmacy claims were used, thus provider-administered 
medications that would show up as procedure codes are excluded. Moreover, as this is a claims-
~120 million enrollees 
(Jan 2009 – Dec 2016)
562,850 with opioid use disorder 
diagnosis
153,022 meeting inclusion criteria
15,592 controls 3,898* cases
1:4 matching
• 18-65 years (n=32,814)
• Benefits
• Prescription (n=48,714)
• Mental Health (n=32,729)
• 6 mos Eligibility (n=198,981)
• Valid enrollment (n=51,655)
• No remission (n=4,786)





based identification of OUD medication, methadone was not captured in the measure of OUD 
medication exposure because it is not dispensed at pharmacies for this indication.  
2.6 NEGATIVE CONTROL 
Association of angiotensin converting enzyme (ACE) inhibitors with OUD remission was 
evaluated as a negative control using the same framework as that for OUD medications as there is 
no direct evidence to suggest that ACE inhibitors would treat OUD. The cohort was created 
identically to that for the primary analysis with the exception that individuals were excluded on 
the basis of ACE inhibitor exposure at baseline rather than OUD medication exposure. ACE 
inhibitors were identified using the GPI 4-digit code (3610x; Appendix D). There were 178,186 
in the final cohort, of whom 6,137 were identified as cases leaving 172,049 potential controls. 
After incidence density sampling, 6,134 cases were matched 4:1 with controls (n=24,536) for 
time at risk, age group, sex, region, and index year. Statistical analyses were identical to those 
implemented for the analysis of OUD medication and remission.  
2.7 COVARIATES 
Age, sex, region, and insurance type were determined from enrollment data at 
baseline. Age was then categorized into an ordinal variable with four levels as follows: 18-26, 27-
35, 36-50, and 51-64 years. Behavioral health visits were defined as the presence of a service 
category on a given claim (Appendix E). Polysubstance use was a binary variable indicating the 
presence (1) or absence (0) of diagnoses for cocaine, amphetamine, alcohol, cannabis, tobacco, or 
other (hallucinogens, sedatives, inhalants, barbiturates) use disorder during the lookback period 
(Appendix F). The presence of concurrent psychiatric disorders was determined using clinical 
classification software (CCS) codes indicating mood disorders (657), anxiety disorders (651), 




disorders (652) during the lookback period23. For analysis, psychiatric disorders were aggregated 
into a single binary variable indicating the presence (1) or absence (0) of CCS codes for any of 
the psychiatric disorders listed. 
2.8 STATISTICAL ANALYSIS 
Descriptive statistics were used to characterize the matched sample, testing for group 
differences with chi-square tests of independence. Conditional logistic regression was used to 
evaluate the association between OUD medication exposure and OUD remission. Adjusted 
models included behavioral health visits, polysubstance use disorders, and psychiatric disorders 
separately and combined. The fully adjusted model included behavioral health visits, 
polysubstance use disorders, and psychiatric disorders as covariates. Due to the large sample size, 
alpha was set at 0.01 for all analyses. All matching and statistical analyses were implemented 
using SAS version 9.4.  
 
CHAPTER 3. RESULTS 
3.1 DEMOGRAPHICS 
There were 153,022 enrollees meeting inclusion criteria for the OUD cohort (Table 1). The 
cohort was primarily male (52.6%), on employer-sponsored health insurance (71.1% vs. health 
plan), from the south region (44.4%), and without a behavioral health visit at baseline (67%). The 
age distribution was similar between all age groups except 27-35 years, which only represented 
13.8% of the cohort. Mood (37.2%) and anxiety disorders (31.4%) were present in about a third 
of the cohort at baseline. Moreover, alcohol (14.4%) and cannabis use disorders (8.3%) were the 
most frequent co-occurring substance use disorders at baseline, consistent with epidemiological 




Table 1. Characteristics of opioid use disorder cohort and matched cases and controls. 
There were 153,022 enrollees meeting inclusion criteria from which 3,898 cases (i.e. enrollees 
with remission diagnosis) were identified and matched 1:4 with controls (i.e. no remission) for 
time at risk, age group, sex, region, and index year. All values represent number with column 
percentages. P-value represents difference between cases and controls. 
 
3.2 MATCHED DEMOGRAPHICS 
The sample was matched on baseline sex, age group, and region, so the distribution of 
these characteristics was identical between cases and controls (Table 1). Compared to controls, a 
higher proportion of cases (54.7%) had concurrent behavioral health visits than controls (35.1%). 
Total Cohort Controls Cases
(n=153022) (n=15592) (n=3898)
Sex 1
Male 80459 (52.6) 9040 (58) 2260 (58)
Female 72563 (47.4) 6552 (42) 1638 (42)
Age Group 1
18-26 39131 (25.6) 7372 (47.3) 1843 (47.3)
27-35 21051 (13.8) 2308 (14.8) 577 (14.8)
36-50 46252 (30.2) 3560 (22.8) 890 (22.8)
≥ 50 46588 (30.5) 2352 (15.1) 588 (15.1)
Region 1
Northeast 29508 (19.3) 3888 (24.9) 972 (24.9)
North Central 29328 (19.2) 3500 (22.5) 875 (22.5)
South 67913 (44.4) 4360 (28) 1090 (28)
West 25369 (16.6) 3800 (24.4) 950 (24.4)
Unknown 904 (0.6) 44 (0.3) 11 (0.3)
Behavioral health visits <.0001
No 102538 (67) 10115 (64.9) 1765 (45.3)
Yes 50484 (33) 5477 (35.1) 2133 (54.7)
Insurance Type 0.0299
Employer 108761 (71.1) 12024 (77.1) 2942 (75.5)
Health plan 44261 (28.9) 3568 (22.9) 956 (24.5)
Employee Relationship 0.0543
Employee 72380 (47.3) 5337 (34.2) 1259 (32.3)
Spouse 46608 (30.5) 3580 (23) 943 (24.2)
Child/other 34034 (22.2) 6675 (42.8) 1696 (43.5)
Substance Use Disorders
Alcohol  22050 (14.4) 1778 (11.4) 722 (18.5) <.0001
Cannabis 12735 (8.3) 1284 (8.2) 473 (12.1) <.0001
Tobacco 5243 (3.4) 347 (2.2) 159 (4.1) <.0001
Amphetamines 4232 (2.8) 481 (3.1) 182 (4.7) <.0001
Cocaine 5856 (3.8) 541 (3.5) 231 (5.9) <.0001
Psychiatric Disorders
Mood Disorders 56888 (37.2) 4633 (29.7) 1705 (43.7) <.0001
Anxiety Disorders 48036 (31.4) 3580 (23) 1416 (36.3) <.0001
Attention-deficit disorders 10390 (6.8) 935 (6) 289 (7.4) 0.0011





Notably, cases were more likely to have concurrent diagnoses of psychiatric and substance use 
disorders than controls.  
3.3 OUD MEDICATION EXPOSURE 
OUD medication exposure during the lookback period was more common in cases than 
controls, such that 6.4% of cases were exposed (i.e. met threshold PDC) compared to 1.7% of 
controls (Figure 4). In the unadjusted analysis, the odds of OUD medication exposure were 4.1 
times greater for cases than controls (Table 2). The adjusted odds ratio for OUD medication 
exposure after adjusting for behavioral health visits, polysubstance use disorders, and psychiatric 
disorders was 3.8 times greater for cases than controls. Stated differently, this suggests that there 
was a 280% increase in the likelihood of OUD medication exposure among cases relative to 
controls. With an unadjusted Experimental Event Rate of 48.5% (i.e. remission among OUD 
medication exposed) and a Control Event Rate of 19.2% (i.e. remission among OUD medication 
non-exposed), the Number Needed to Treat is 3.4. Specifically, 3.4 individuals need to be treated 
in order for 1 to experience remission.   
Figure 4. Proportion of cases and controls with medication exposure. (A) Of the 15,592 
controls (i.e. no remission), 263 (1.7%) had exposure to opioid use disorder (OUD) medications 
prior to the lookback date. Among 3,898 cases (i.e. enrollees with remission diagnosis), 248 
(6.4%) had prior exposure to OUD medications. (B) Although there were far fewer new-users of 
angiotensin converting enzyme (ACE) inhibitors (different x-axis), the proportion of exposed did 





3.4 NEGATIVE CONTROL 
Cases were no more likely than controls to have ACE inhibitor exposure during the 
lookback period. Adjusted and unadjusted analyses indicated that the odds of ACE inhibitor 
exposure were not significantly different from 1 (Table 2).  
Table 2. Conditional logistic regression analyses of opioid use disorder medications or 
angiotensin converting enzyme inhibitors with remission. The odds of opioid use disorder 
(OUD) medication exposure were consistently 3.7 to 4.1 times higher in cases (i.e. enrollees with 
remission) than controls (i.e. enrollees without remission) in matched unadjusted and adjusted 
models. In contrast, there was no evidence to suggest that angiotensin converting enzyme (ACE) 
inhibitors were significantly associated with remission.   
 
 
CHAPTER 4. DISCUSSION 
4.1 GENERAL 
This work demonstrates the feasibility of using administrative health claims data to 
evaluate the effectiveness of medications used to treat substance use disorders. Moreover, this 
work lays the foundation for computational repurposing strategies25 to be applied using 
administrative claims data, especially in the context of substance use disorders. In this test 
case, we evaluated the association of a remission diagnosis with previous exposure to medications 
known to treat OUD that are available by prescription15–17. As expected from randomized control 
trials, this nested case control analysis found consistent increases in the odds of exposure to OUD 
medications among individuals who had remission (cases) compared to controls. Importantly, 
these findings support the use of remission diagnoses as a proxy for medication effectiveness in 
the context of substance use disorders. Although it would be compelling to test the workflow in 
OR 99% CI p-value OR 99% CI p-value
4.1 3.3, 5.3 <0.001 0.8 0.25, 2.5 0.6179
Behavioral Health Visits 3.7 2.9, 4.8 <0.001 0.89 0.29, 2.8 0.7982
Polysubstance Use Disorders 4.1 3.2, 5.3 <0.001 0.83 0.26, 2.6 0.6740
Psychiatric Disorders 4.0 3.1, 5.1 <0.001 0.82 0.26, 2.6 0.6614
Fully 3.8 3.0, 4.9 <0.001 0.90 0.28, 2.9 0.8208
OR:Odds Ratio; CI: confidence interval







the context of a physiological disease (e.g. insulin for diabetes) to ascertain reasonable effect 
sizes, the treatment of behavioral disorders is vastly different from physiological diseases and 
diagnostic codes for most diseases do not indicate the absence of a condition. Ultimately, the goal 
of this research is to generalize this approach to other substance use disorders for which there are 
no FDA-approved pharmacotherapies (e.g. stimulant use disorders). These findings suggest that 
this is a viable approach for such pursuits and establishes the framework for using health claims 
data for computational repurposing, which is the use of automated workflows to generate 
candidate medication leads for repurposing.  
This study demonstrates the ability of the application of the repurposing workflow to 
health claims data to recapitulate small randomized controlled trials of the effect of medications 
used to treat OUD. Moreover, to demonstrate the specificity of the approach, the association 
between ACE inhibitors and OUD remission was assessed. As expected, there was no association 
between exposure to ACE inhibitors and OUD remission. ACE inhibitors are prescribed for 
hypertension and work by inhibiting the production of angiotensin II, which is a hormone that 
increases vasoconstriction. As yet, there is no direct evidence to suggest that ACE inhibitors 
would be associated with outcomes of OUD. However, there is evidence that ACE inhibitors have 
central actions, including increasing dopamine in the striatum26–28. Some studies have also 
demonstrated that ACE inhibitors can alter the subjective effects of other drugs of abuse like 
methamphetamine, but these tended to be cardiovascular in nature rather than psychological (i.e., 
drug-liking and high)29,30. Future work will evaluate alternate medications as negative controls to 
further substantiate the specificity of the approach to appropriately rule out medications with no 
known treatment effect. 
4.2 LIMITATIONS & FUTURE DIRECTIONS 
One of the primary limitations of the workflow is in using remission as the outcome, as 




substantially limiting the sample of individuals with the outcome of interest. Based on medical 
coding guidelines and conversations with clinicians, a diagnosis of remission is up to the 
discretion of the provider, in part, because there are no biomarkers for substance use disorders. As 
such, many individuals who are in fact in remission are likely to be misclassified as not having 
remission. The rare coding and uncertainty regarding remission diagnoses as beneficial outcomes 
are likely to be the primary limitations in the application of this medication repurposing workflow 
moving forward. As such, it will be necessary to determine alternative outcomes that are more 
frequently observed in administrative data that can be used as outcomes (emergency department 
visits, healthcare expenditures, and healthcare utilization)31.  
The use of administrative pharmacy claims data to measure medication exposure presents 
some limitations. Specific to OUD medications is that methadone for OUD was not available in 
claims data as it is provided by Opioid Treatment Programs, which in 2015 provided methadone 
to 356,843 clients32. As such, it is possible that individuals being treated for OUD with 
methadone were misclassified as having no treatment since this could not be measured with the 
available data. However, after matching for age, sex, region, and year, it is unlikely that there 
would be systematic differences between cases and controls in methadone exposure. A more 
general limitation of using pharmacy claims to measure medication exposure is that filling a 
prescription does not guarantee that an individual took the medication. For this reason, in the 
primary analysis OUD medication exposure was defined as having greater than or equal to 80% 
PDC33.  
A further limitation of this study has to do with generalizability. The study was conducted 
using individuals with commercial health insurance, and as such, the findings may not be 
representative of individuals with OUD. Although nearly 50% of the United States has 
commercial health insurance18, individuals with substance use disorders are generally 
overrepresented in the uninsured category. Specifically, between 2007 and 2013, 24% of 




availability of sociocultural variables in this administrative dataset, there is the potential for 
unmeasured confounders. Ultimately, expanded or linked datasets will be valuable to account for 
sociodemographic confounders as this medication repurposing workflow continues to be 
developed. It will also be valuable to replicate these findings in an alternative data source, such as 
using Medicaid claims where the prevalence of substance use disorders is more than double that 
of some commercial populations19.  
 
Figure 5. Reverse-translational repurposing pipeline. Similar to the de novo drug discovery 
pipeline, the claims-based reverse-translational repurposing pipeline would start with many 
candidates (individual and combination medications) identified through data mining. Those 
candidates generated through data mining would then be evaluated using the nested case control 
analysis described here. Candidates that passed the nested case-control screen would then go on 
to further reverse-translational analysis, which could include preclinical or cell-based assays. 
Importantly, this reverse-translational pipeline could have the potential to identify novel 
mechanisms of treatment for stimulant use disorders.  
4.3 CONCLUSIONS 
The findings presented here demonstrate the feasibility of using administrative health 
claims data to evaluate the effectiveness of medications to treat substance use disorders. Notably, 
using remission as an outcome appears to serve as a proxy for medication effectiveness, at least in 
the context of OUDs. These findings also provide an effect size benchmark for future studies in 
evaluating the effectiveness of other medications to treat substance use disorders. Importantly, 




combine data mining and pharmacoepidemiologic strategies to advance medications discoveries 
for substance use disorders. Similar to the de novo drug discovery pipeline, the vision for the 
reverse-translational medication repurposing pipeline is to discover many candidate medications 
and systematically screen them for potential to be repurposed (Figure 5). Specifically, applying 
data mining to health claims data can discover medications (i.e. identify targets) that frequently 
co-occur among individuals who have remission. These individual or combination medications 
can then be further screened using the nested case-control analysis presented here. Medications 
generated and validated using this pipeline can then be subject to further reverse-translation using 
preclinical or cell-based assays. Notably, this approach could identify novel mechanisms of 
treatment for stimulant use disorders based on the reverse-translational analyses. The next steps 
will be to apply the repurposing workflow back to stimulant use disorders by first generating 
candidate medications and combinations using data mining that will then be evaluated using a 
retrospective analysis (Figure 1). This data-driven repurposing approach has the potential to 
inform research along the translational-science spectrum, ranging from in vitro assays to animal 
models to clinical trials (Figure 6), ultimately advancing medications discoveries for substance 
use disorders.  
 
Figure 6. Integration of data-driven repurposing into translational science cycle. The goal of 






Appendix A: Diagnostic codes to identify opioid use disorder 
 
 
ICD codes Version LABEL
304 ICD-9-CM Opioid type dependence unsp use
304.01 ICD-9-CM Opioid dependence continuous
304.02 ICD-9-CM Opioid dependence episodic
304.7 ICD-9-CM Opioid/Oth dependence unsp
304.71 ICD-9-CM Opioid/Oth dependence continuous
304.72 ICD-9-CM Opioid/Oth dependence episodic
305.5 ICD-9-CM Nondep opioid abuse unsp use
305.51 ICD-9-CM Nondep opioid abuse continuous use
305.52 ICD-9-CM Nondep opioid abuse episodic use
F11.10 ICD-10-CM Opioid abuse, uncomplicated
F11.120 ICD-10-CM Opioid abuse with intoxication, uncomplicated
F11.121 ICD-10-CM Opioid abuse with intoxication delirium
F11.122 ICD-10-CM Opioid abuse with intoxication with perceptual disturbance
F11.129 ICD-10-CM Opioid abuse with intoxication, unspecified
F11.14 ICD-10-CM Opioid abuse with opioid-induced mood disorder
F11.150 ICD-10-CM Opioid abuse with opioid-induced psychotic disorder with delusions
F11.151 ICD-10-CM Opioid abuse with opioid-induced psychotic disorder with hallucinations
F11.159 ICD-10-CM Opioid abuse with opioid-induced psychotic disorder, unspecified
F11.181 ICD-10-CM Opioid abuse with opioid-induced sexual dysfunction
F11.182 ICD-10-CM Opioid abuse with opioid-induced sleep disorder
F11.188 ICD-10-CM Opioid abuse with other opioid-induced disorder
F11.19 ICD-10-CM Opioid abuse with unspecified opioid-induced disorder
F11.20 ICD-10-CM Opioid dependence, uncomplicated
F11.220 ICD-10-CM Opioid dependence with intoxication, uncomplicated
F11.221 ICD-10-CM Opioid dependence with intoxication delirium
F11.222 ICD-10-CM Opioid dependence with intoxication with perceptual disturbance
F11.229 ICD-10-CM Opioid dependence with intoxication, unspecified
F11.23 ICD-10-CM Opioid dependence with withdrawal
F11.24 ICD-10-CM Opioid dependence with opioid-induced mood disorder
F11.250 ICD-10-CM Opioid dependence with opioid-induced psychotic disorder with delusions
F11.251 ICD-10-CM Opioid dependence with opioid-induced psychotic disorder with hallucinations
F11.259 ICD-10-CM Opioid dependence with opioid-induced psychotic disorder, unspecified
F11.281 ICD-10-CM Opioid dependence with opioid-induced sexual dysfunction
F11.282 ICD-10-CM Opioid dependence with opioid-induced sleep disorder
F11.288 ICD-10-CM Opioid dependence with other opioid-induced disorder
F11.29 ICD-10-CM Opioid dependence with unspecified opioid-induced disorder
F11.1 ICD-10-CM Opioid abuse 
F11.12 ICD-10-CM Opioid abuse with intoxication 
F11.15 ICD-10-CM Opioid abuse with opioid-induced psychotic disorder 
F11.18 ICD-10-CM Opioid abuse with other opioid-induced disorder 
F11.2 ICD-10-CM Opioid dependence 
F11.22 ICD-10-CM Opioid dependence with intoxication 
F11.25 ICD-10-CM Opioid dependence with opiod-induced psychotic disorder 




Appendix B: Diagnostic codes to identify remission 
 
 
ICD codes Version LABEL
304.03 ICD-9-CM Opioid type dependence remiss
304.73 ICD-9-CM Opioid/oth dependence remiss
305.53 ICD-9-CM Nondep opioid abuse remiss
F11.11 ICD-10-CM Opioid abuse, in remission 











65200010200715 Buprenorphine HCl-Naloxone HCl SL Tab 1.4-0.36 MG (Base Eq)
65200010208240 Buprenorphine HCl-Naloxone HCl SL Film 8-2 MG (Base Equiv)
65200010200760 Buprenorphine HCl-Naloxone HCl SL Tab 11.4-2.9 MG (Base Eq)
65200010208280 Buprenorphine-Naloxone Buccal Film 6.3-1 MG (Base Equiv)
65200010208260 Buprenorphine-Naloxone Buccal Film 2.1-0.3 MG (Base Equiv)
65200010200732 Buprenorphine HCl-Naloxone HCl SL Tab 5.7-1.4 MG (Base Eq)
65200010200745 Buprenorphine HCl-Naloxone HCl SL Tab 8.6-2.1 MG (Base Eq)
65200010208270 Buprenorphine-Naloxone Buccal Film 4.2-0.7 MG (Base Equiv)
65200010208220 Buprenorphine HCl-Naloxone HCl SL Film 2-0.5 MG (Base Equiv)
65200010200740 Buprenorphine HCl-Naloxone HCl SL Tab 8-2 MG (Base Equiv)
65200010208250 Buprenorphine HCl-Naloxone HCl SL Film 12-3 MG (Base Equiv)
65200010200720 Buprenorphine HCl-Naloxone HCl SL Tab 2-0.5 MG (Base Equiv)
65200010200725 Buprenorphine HCl-Naloxone HCl SL Tab 2.9-0.71 MG (Base Eq)
65200010208230 Buprenorphine HCl-Naloxone HCl SL Film 4-1 MG (Base Equiv)
65200010102320 Buprenorphine HCl Subdermal Implant 74.2 MG (Base Equiv)
65200010100760 Buprenorphine HCl SL Tab 2 MG (Base Equiv)
65200010100780 Buprenorphine HCl SL Tab 8 MG (Base Equiv)
93400030001920 Naltrexone For IM Extended Release Susp 380 MG




Appendix D: Angiotensin converting enzyme inhibitors  
 
   
Medi-Span GPI LABEL
3610x
Accupril, Aceon, Altace, Benazepril HCl, Capoten, Captopril, Enalapril 
Maleate, Enalaprilat, Epaned, Fosinopril Sodium, Lisinopril, Lotensin, Mavik, 
Moexipril HCl, Monopril, Perindopril Erbumine, Prinivil, Qbrelis, Quinapril HCl, 










31118 Substance Abuse Facility IP Behavioral Health Therapy
31418 Substance Abuse Facility OP Behavioral Health Therapy
31518 Substance Abuse Physician OP Behavioral Health Therapy
31618 Substance Abuse Professional OP Behavioral Health Therapy
30218 Mental Health Physician IP Behavioral Health Therapy
30118 Mental Health Facility IP Behavioral Health Therapy
30418 Mental Health Facility OP Behavioral Health Therapy
30518 Mental Health Physician OP Behavioral Health Therapy
30618 Mental Health Professional OP Behavioral Health Therapy
31218 Substance Abuse Physician IP Behavioral Health Therapy
31318 Substance Abuse Professional IP Behavioral Health Therapy








Substance ICD-9-CM and ICD-10-CM codes
Amphetamine
304.40, 304.41, 304.42, 305.70, 305.71, 305.72, F15.10, F15.120, F15.121, 
F15.122, F15.129, F15.14, F15.150, F15.151, F15.159, F15.180, F15.181, 
F15.182, F15.188, F15.19, F15.20, F15.220, F15.221, F15.222, F15.229, 
F15.23, F15.24, F15.250, F15.251, F15.259, F15.280, F15.281, F15.282, 
F15.288, F15.29, F15.90, F15.920, F15.921, F15.922, F15.929, F15.93, 
F15.94, F15.950, F15.951, F15.959, F15.980, F15.981, F15.982, F15.988, 
F15.99
Cocaine
304.20, 304.21, 304.22, 305.60, 305.61, 305.62, F14.10, F14.120, F14.121, 
F14.122, F14.129, F14.14, F14.150, F14.151, F14.159, F14.180, F14.181, 
F14.182, F14.188, F14.19, F14.20, F14.220, F14.221, F14.222, F14.229, 
F14.23, F14.24, F14.250, F14.251, F14.259, F14.280, F14.281, F14.282, 
F14.288, F14.29, F14.90, F14.920, F14.921, F14.922, F14.929, F14.94, 
F14.950, F14.951, F14.959, F14.980, F14.981, F14.982, F14.988, F14.99
Cannabis
304.30, 304.31, 304.32, 305.20, 305.21, 305.22, F12.10, F12.120, F12.121, 
F12.122, F12.129, F12.150, F12.151, F12.159, F12.180, F12.188, F12.19, 
F12.20, F12.220, F12.221, F12.222, F12.229, F12.250, F12.251, F12.259, 
F12.280, F12.288, F12.29, F12.90, F12.920, F12.921, F12.922, F12.929, 
F12.950, F12.951, F12.959, F12.980, F12.988, F12.99
Alcohol
303.90, 303.91, 303.92, 305.00, 305.01, 305.02, F10.10, F10.120, F10.121, 
F10.129, F10.14, F10.150, F10.151, F10.159, F10.180, F10.181, F10.182, 
F10.188, F10.19, F10.20, F10.220, F10.221, F10.229, F10.230, F10.231, 
F10.232, F10.239, F10.24, F10.250, F10.251, F10.259, F10.26, F10.27, 
F10.280, F10.281, F10.282, F10.288, F10.29, F10.920, F10.921, F10.929, 
F10.94, F10.950, F10.951, F10.959, F10.96, F10.97, F10.980, F10.981, 
F10.982
Tobacco
305.1, 305.10, 305.11, 305.12, F17.200, F17.203, F17.208, F17.209, F17.210, 
F17.213, F17.218, F17.219, F17.220, F17.223, F17.228, F17.229, F17.290, 






304.10, 304.11, 304.12, 305.40, 305.41, 305.42, 304.50, 304.51, 304.52, 
305.30, 305.31, 305.32, F13.10, F13.120, F13.121, F13.129, F13.14, F13.150, 
F13.151, F13.159, F13.180, F13.181, F13.182, F13.188, F13.19, F13.20, 
F13.220, F13.221, F13.229, F13.230, F13.231, F13.232, F13.239, F13.24, 
F13.250, F13.251, F13.259, F13.26, F13.27, F13.280, F13.281, F13.282, 
F13.288, F13.29, F13.90, F13.920, F13.921, F13.929, F13.930, F13.931, 
F13.932, F13.939, F13.94, F13.950, F13.951, F13.959, F13.96, F13.97, 
F13.980, F13.981, F13.982, F13.988, F13.99, F16.10, F16.120, F16.121, 
F16.122, F16.129, F16.14, F16.150, F16.151, F16.159, F16.180, F16.183, 
F16.188, F16.19, F16.20, F16.220, F16.221, F16.229, F16.24, F16.250, 
F16.251, F16.259, F16.280, F16.283, F16.288, F16.29, F16.90, F16.920, 
F16.921, F16.929, F16.94, F16.950, F16.951, F16.959, F16.980, F16.983, 
F16.988, F16.99, F18.10, F18.120, F18.121, F18.129, F18.14, F18.150, 
F18.151, F18.159, F18.17, F18.180, F18.188, F18.19, F18.20, F18.220, 
F18.221, F18.229, F18.24, F18.250, F18.251, F18.259, F18.27, F18.280, 
F18.288, F18.29, F18.90, F18.920, F18.921, F18.929, F18.94, F18.950, 
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